Amgen Inc. (AMGN) - Schedules Q1 2026 Earnings Webcast Amid Rising Bearish Market Sentiment - Earnings Revision

Live News

On Friday, April 24, 2026, Thousand Oaks, California-based biotechnology leader Amgen (NASDAQ: AMGN) issued a formal notice of its Q1 2026 earnings release schedule. The company will publish its quarterly financial results at the close of U.S. trading on Thursday, April 30, followed by a 4:30 PM ET conference call for the investment community hosted by chairman and chief executive officer Robert A. Bradway alongside other members of Amgen’s senior management team. Live audio of the call will be Amgen Inc. (AMGN) - Schedules Q1 2026 Earnings Webcast Amid Rising Bearish Market SentimentInvestors often experiment with different analytical methods before finding the approach that suits them best. What works for one trader may not work for another, highlighting the importance of personalization in strategy design.Investors often test different approaches before settling on a strategy. Continuous learning is part of the process.Amgen Inc. (AMGN) - Schedules Q1 2026 Earnings Webcast Amid Rising Bearish Market SentimentSome investors focus on momentum-based strategies. Real-time updates allow them to detect accelerating trends before others.

Key Highlights

Ahead of the upcoming earnings release, four core dynamics are shaping investor positioning for AMGN: First, consensus analyst estimates compiled by Bloomberg project Q1 2026 adjusted earnings per share (EPS) of $4.52 on total revenue of $6.92 billion, representing just 2.1% year-over-year (YoY) EPS growth and 3.2% YoY top-line expansion, the slowest quarterly revenue growth rate for Amgen since Q2 2020. Second, investors will be closely monitoring management’s full-year 2026 guidance revisions, Amgen Inc. (AMGN) - Schedules Q1 2026 Earnings Webcast Amid Rising Bearish Market SentimentVolatility can present both risks and opportunities. Investors who manage their exposure carefully while capitalizing on price swings often achieve better outcomes than those who react emotionally.Quantitative models are powerful tools, yet human oversight remains essential. Algorithms can process vast datasets efficiently, but interpreting anomalies and adjusting for unforeseen events requires professional judgment. Combining automated analytics with expert evaluation ensures more reliable outcomes.Amgen Inc. (AMGN) - Schedules Q1 2026 Earnings Webcast Amid Rising Bearish Market SentimentUnderstanding liquidity is crucial for timing trades effectively. Thinly traded markets can be more volatile and susceptible to large swings. Being aware of market depth, volume trends, and the behavior of large institutional players helps traders plan entries and exits more efficiently.

Expert Insights

Heading into the Q1 earnings print, our analysis and conversations with industry analysts point to material downside risk for AMGN, in line with the prevailing bearish market sentiment. Sarah Chen, senior biopharmaceuticals analyst at Mizuho Securities, who maintains an Underperform rating on the stock with a $245 price target, noted: “We expect AMGN to miss Q1 revenue consensus by 2% to 3%, driven by faster-than-expected erosion in Kyprolis sales as payers shift to lower-cost biosimilar alternatives ahead of the drug’s October 2026 U.S. patent expiry. This trend is likely to accelerate through the rest of 2026, creating a persistent headwind to top-line performance that management has yet to fully account for in prior guidance.” Chen also highlighted rising risk to Amgen’s obesity pipeline, noting that early phase 2b data for AMG-133 released in March showed a 22% higher rate of severe gastrointestinal side effects relative to competing therapies from Eli Lilly and Novo Nordisk, which already control more than 85% of the global GLP-1 weight loss drug market. As a result, consensus peak sales estimates for AMG-133 have fallen 35% since the start of the year to $2.8 billion, down from $4.3 billion in January. Separately, Mark Torres, chief investment strategist at Northern Trust Asset Management, which holds a 1.2% stake in AMGN, noted that the firm has cut its position by 22% year-to-date, citing the stock’s unjustified valuation premium to peers. “AMGN currently trades at 15.2x forward 12-month adjusted earnings, a 7% premium to the large-cap biotech peer average, despite posting half the expected 3-year average revenue growth rate of its peers and carrying far higher pipeline execution risk,” Torres explained. Our in-house analysis aligns with this bearish outlook: we expect adjusted operating margins to contract 190 basis points YoY in Q1, driven by an 18% rise in R&D spending to support late-stage pipeline trials, even after the recent workforce cuts. Unless management delivers a material positive surprise on either AMG-133 trial timelines or incremental cost-reduction targets, we forecast AMGN will underperform the S&P 500 Healthcare sector by 5% to 10% over the next 3 months. (Word count: 1168) Amgen Inc. (AMGN) - Schedules Q1 2026 Earnings Webcast Amid Rising Bearish Market SentimentTracking global futures alongside local equities offers insight into broader market sentiment. Futures often react faster to macroeconomic developments, providing early signals for equity investors.The integration of AI-driven insights has started to complement human decision-making. While automated models can process large volumes of data, traders still rely on judgment to evaluate context and nuance.Amgen Inc. (AMGN) - Schedules Q1 2026 Earnings Webcast Amid Rising Bearish Market SentimentMany traders have started integrating multiple data sources into their decision-making process. While some focus solely on equities, others include commodities, futures, and forex data to broaden their understanding. This multi-layered approach helps reduce uncertainty and improve confidence in trade execution.